NGF leadership Dompé is a pioneer in nerve growth factor (NGF) therapeutics with disease-modifying approaches, presenting opportunities to partner on ophthalmic, neurological, and pain indications where NGF-based therapies may offer differentiated outcomes.

First-in-class potential The company has a track record of advancing first-in-class biologies and recently achieved topical biologic approval for a rare neurotrophic eye disease, indicating readiness for collaborations that accelerate novel delivery platforms and regulatory pathways.

Global expansion Dompé has a history of international development, including North American R&D coordination since 2014, signaling potential for co-development, regional manufacturing partnerships, and commercial alliances across key markets.

Strategic partnerships Recent collaborations with Eurofins Discovery and integration of AI-enabled discovery platforms suggest appetite for external scientific partnerships, data-driven drug discovery, and leverage of computational biology in early programs.

Access and funding Participation in FDA priority programs and patient access initiatives, along with a mid-size revenue range, indicate opportunities for value-based collaborations, patient support programs, and market-access-focused partnerships.